Jounce Therapeutics Inc (NASDAQ:JNCE) shot up 6.8% during mid-day trading on Monday . The stock traded as high as $8.97 and last traded at $8.85. 929,804 shares traded hands during trading, an increase of 56% from the average session volume of 596,804 shares. The stock had previously closed at $8.29.
A number of research analysts recently commented on the stock. Raymond James reaffirmed a “buy” rating and issued a $12.00 price target on shares of Jounce Therapeutics in a report on Wednesday, September 2nd. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Jounce Therapeutics in a research note on Friday, August 21st. HC Wainwright boosted their target price on Jounce Therapeutics from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Zacks Investment Research lowered Jounce Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 13th. Finally, BidaskClub raised shares of Jounce Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 11th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $9.00.
The stock has a market capitalization of $373.05 million, a P/E ratio of 16.27 and a beta of 2.11. The stock’s fifty day moving average price is $5.57 and its 200 day moving average price is $5.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.04 and a quick ratio of 8.04.
Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.10). On average, sell-side analysts expect that Jounce Therapeutics Inc will post -2.99 earnings per share for the current year.
In other news, CFO Kimberlee C. Drapkin sold 7,200 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $8.06, for a total transaction of $58,032.00. Following the transaction, the chief financial officer now owns 61,708 shares of the company’s stock, valued at approximately $497,366.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 11,110 shares of company stock valued at $76,378. 43.96% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in JNCE. Advisor Group Holdings Inc. increased its holdings in Jounce Therapeutics by 46.5% during the second quarter. Advisor Group Holdings Inc. now owns 6,858 shares of the company’s stock valued at $47,000 after buying an additional 2,178 shares during the period. Grantham Mayo Van Otterloo & Co. LLC purchased a new position in shares of Jounce Therapeutics in the 1st quarter valued at $49,000. Raymond James & Associates bought a new position in shares of Jounce Therapeutics in the 1st quarter worth $61,000. Captrust Financial Advisors purchased a new stake in shares of Jounce Therapeutics during the 2nd quarter worth $73,000. Finally, AJO LP boosted its position in Jounce Therapeutics by 31.4% during the first quarter. AJO LP now owns 17,460 shares of the company’s stock valued at $82,000 after purchasing an additional 4,168 shares in the last quarter. 74.08% of the stock is owned by hedge funds and other institutional investors.
About Jounce Therapeutics (NASDAQ:JNCE)
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
See Also: Is a Roth IRA right for you?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.